Incidence of adenocarcinoma among patients with Barrett's esophagus
- PMID: 21995385
- DOI: 10.1056/NEJMoa1103042
Incidence of adenocarcinoma among patients with Barrett's esophagus
Abstract
Background: Accurate population-based data are needed on the incidence of esophageal adenocarcinoma and high-grade dysplasia among patients with Barrett's esophagus.
Methods: We conducted a nationwide, population-based, cohort study involving all patients with Barrett's esophagus in Denmark during the period from 1992 through 2009, using data from the Danish Pathology Registry and the Danish Cancer Registry. We determined the incidence rates (numbers of cases per 1000 person-years) of adenocarcinoma and high-grade dysplasia. As a measure of relative risk, standardized incidence ratios were calculated with the use of national cancer rates in Denmark during the study period.
Results: We identified 11,028 patients with Barrett's esophagus and analyzed their data for a median of 5.2 years. Within the first year after the index endoscopy, 131 new cases of adenocarcinoma were diagnosed. During subsequent years, 66 new adenocarcinomas were detected, yielding an incidence rate for adenocarcinoma of 1.2 cases per 1000 person-years (95% confidence interval [CI], 0.9 to 1.5). As compared with the risk in the general population, the relative risk of adenocarcinoma among patients with Barrett's esophagus was 11.3 (95% CI, 8.8 to 14.4). The annual risk of esophageal adenocarcinoma was 0.12% (95% CI, 0.09 to 0.15). Detection of low-grade dysplasia on the index endoscopy was associated with an incidence rate for adenocarcinoma of 5.1 cases per 1000 person-years. In contrast, the incidence rate among patients without dysplasia was 1.0 case per 1000 person-years. Risk estimates for patients with high-grade dysplasia were slightly higher.
Conclusions: Barrett's esophagus is a strong risk factor for esophageal adenocarcinoma, but the absolute annual risk, 0.12%, is much lower than the assumed risk of 0.5%, which is the basis for current surveillance guidelines. Data from the current study call into question the rationale for ongoing surveillance in patients who have Barrett's esophagus without dysplasia. (Funded by the Clinical Institute, University of Aarhus, Aarhus, Denmark.).
Comment in
-
The problems with surveillance of Barrett's esophagus.N Engl J Med. 2011 Oct 13;365(15):1437-8. doi: 10.1056/NEJMe1108435. N Engl J Med. 2011. PMID: 21995392 No abstract available.
-
Barrett esophagus: Need for ongoing surveillance called into question for patients with non-dysplastic Barrett esophagus.Nat Rev Gastroenterol Hepatol. 2011 Dec 5;8(12):657. doi: 10.1038/nrgastro.2011.204. Nat Rev Gastroenterol Hepatol. 2011. PMID: 22138905 No abstract available.
-
Adenocarcinoma in Barrett's esophagus.N Engl J Med. 2011 Dec 29;365(26):2539; author reply 2539-40. doi: 10.1056/NEJMc1113052. N Engl J Med. 2011. PMID: 22204731 No abstract available.
-
[Risk of adenocarcinoma in patients with Barrett esophagus is significantly less than previously assumed].Praxis (Bern 1994). 2012 Jan 4;101(1):59-60. doi: 10.1024/1661-8157/a000811. Praxis (Bern 1994). 2012. PMID: 22219077 German. No abstract available.
-
Reflux and Barrett's disease. Can we stop surveillance after 2011?Endoscopy. 2012 Apr;44(4):362-5. doi: 10.1055/s-0031-1291741. Epub 2012 Feb 27. Endoscopy. 2012. PMID: 22370699 No abstract available.
-
Where is the truth when it comes to cancer risk in Barrett's esophagus?Gastroenterology. 2012 May;142(5):1245-7. doi: 10.1053/j.gastro.2012.03.017. Epub 2012 Mar 20. Gastroenterology. 2012. PMID: 22445710 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous